SPOTLIGHT: FDA orders halt to nausea drug


The FDA has ordered drug makers to stop making anti-nausea suppositories that contain the active ingredient trimethobenzamide, saying they are ineffective. The move is part of a wider effort by the FDA to take a second look at drugs approved before 1962, when developers had to prove that a drug would do no harm as the main condition for approval. Some two million of the suppositories are sold each year. The agency estimates that there are several hundred unapproved active ingredients in use today. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.